Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q2 EPS of ($1.02), $0.34 better than the analyst estimate of ($1.36). Revenue for the quarter came in at $95 million versus the consensus estimate of $70.24 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.